A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
NCT04630860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2023-05-16
Summary
This study is to evaluate the pharmacokinetics and safety of LY03003 in patients with advanced-stage PD.
Conditions
- Parkinson Disease
Interventions
- DRUG
-
LY03003
Rotigotine,extended-release microspheres
Sponsors & Collaborators
-
Luye Pharma Group Ltd.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-07
- Primary Completion
- 2021-05-12
- Completion
- 2022-01-25
Countries
- China
Study Locations
More Related Trials
-
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
NCT04571164 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
NCT02055274 ·Status: COMPLETED ·Phase: PHASE1
-
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers
NCT04593511 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400 ·Status: RECRUITING ·Phase: PHASE1
-
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
NCT02649608 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease
NCT04455555 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD
NCT05882487 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Study of LY300164 for the Treatment of Parkinson's Disease
NCT00004576 ·Status: COMPLETED ·Phase: PHASE2
-
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
NCT07157345 ·Status: RECRUITING ·Phase: PHASE1
-
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
NCT07028632 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
NCT07195825 ·Status: RECRUITING ·Phase: PHASE1
-
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
NCT00036205 ·Status: TERMINATED ·Phase: PHASE3
-
Infusion of Apomorphine: Long-term Safety Study
NCT02339064 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
NCT06216054 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
NCT06565195 ·Status: RECRUITING ·Phase: PHASE1
-
A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease
NCT06195124 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
NCT02562768 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
NCT06731868 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
NCT04384666 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
NCT03716570 ·Status: TERMINATED ·Phase: PHASE1
-
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
NCT03272165 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
NCT07080775 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
NCT07106021 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
NCT06480461 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
NCT05238701 ·Status: COMPLETED ·Phase: PHASE1